Sort by
Simulation-Based Planning of Electric Vehicle Charging Infrastructure Along a TEN-T Transport Corridor Under Increasing EV Adoption
Marek Lis
,Maksymilian Mądziel
Posted: 17 April 2026
The Integration of the SDGs into Monetary Policy and the Green Transition
Valentina Vasile
,Otilia Manta
,Aurora Moldoveanu (Cojocariu)
,Boni-Mihaela Straoanu
Posted: 17 April 2026
Response Surface Modeling and Molecular Docking to Predict the Antifungal Properties of Mespilodaphne quixos (Lam.) Rohwer Essential Oil Against Candida albicans
Yasiel Arteaga-Crespo
,Yudel García-Quintana
,Yendrek Velásquez López
,Matteo Radice
,Mariana Magdalena Conforme-García
,Jannys Lizeth Rivera Barreto
,José Blanco-Salas
,Reinier Abreu-Naranjo
Posted: 17 April 2026
Oral Mycobiome: Composition, Functionality and Clinical Implication
Geovani Moreira Cruz
,Amanda Siqueira Fraga
,Maíra Terra Garcia
,Juliana Campos Junqueira
Posted: 17 April 2026
Financial Intermediation and Provincial Economic Activity in a Dollarized Economy: Panel VAR Evidence from Ecuador
Félix Casares-Conforme
,Ángel Maridueña-Larrea
,Rocío Isabel González-Reyes
,Javier Patricio Cadena-Silva
,Patricio Rigoberto Alvarez-Muñoz
Posted: 17 April 2026
Epigenetic Modulation of Diabetes Mellitus by Plant-Derived Polyphenols: Mechanistic insights and Therapeutic Prospects
Ashvima M. P.
,Manjuvarshini R.
,Preetha Nair
,Hema Negi
Posted: 17 April 2026
Guide to Spintronic Crossbar Arrays: From Binary Switches to Analog Computing
Pietro Perlo
Posted: 17 April 2026
Smart Wearable Inhalers for Chronic Respiratory Care in Advanced Lung Cancer
Karthick R
Posted: 17 April 2026
Kinesiophobia and Work Disability in Fibromyalgia: Cognitive Mediation in a Population-Based Study
Giordano Mayer De Freitas
,Guilherme Teixeira Lopes
,Graziele Borges Bueno
,Mariana Lentino Coelho
,Julia Gomes
,Caroline Leffa Venturini
,Maria Eduarda Louzada
,Sara Machado Peres
,Bárbara Regina França
,Iraci LS Torres
+3 authors
Posted: 16 April 2026
Multivariate And Multidimensional Quality Gain-Loss Function and Its Applications Based on Nonseparable Gaussian Processes
Aili Wang
,Xianfei Chen
,Jiahang Liu
,Shunan Tong
,Yizhou Li
,Tianyu Fan
Posted: 16 April 2026
A Hybrid TCN-Attention-BiLSTM Framework for AIS-Based Nearshore Vessel Speed Prediction and Risk Warning
Xin Liu
,Zhaona Chen
,Yu Cao
,Dan Zhang
Posted: 16 April 2026
A Possible Approach for Electric Charge Quantization by a Tiny Kerr Black Hole Net
Tongsheng Xia
Posted: 16 April 2026
Incidental Findings on Abdominal X-Rays—Worry, Watch, or Leave Alone?
Shirom Rajeev Siriwardana
,H. G. Supunika Kumari
Posted: 16 April 2026
A Blueprint for Connection: Mapping Pathways of Relationship Change in Couples Using the Agapé App
Ronald D. Rogge
,Jenna A. Macri
,Khadesha Okwudili
,Dev Crasta
Posted: 16 April 2026
Bio-Based Construction Materials in the Context of the EU Bioeconomy: Overcoming Systemic Barriers to Mainstream Adoption
F. Pacheco-Torgal
Posted: 16 April 2026
The Role of Trpv6 in Pancreatic Ductal Cells and Pancreatic Cancer: Expression, Mechanisms, and Therapeutic Perspectives
Boshra Yosef
,Viktória Venglovecz
Posted: 16 April 2026
Precision Medicine Treatment of Alzheimer’s Disease: Successful Randomized Controlled Trial
Kat Toups
,Craig P. Tanio
,Ann Hathaway
,Nate Bergman
,Kristine Burke
,David Haase
,Susan Cole
,Stephen L. Aita
,Cyrus Raji
,Alan Boyd
+13 authors
Background: There is a critical need for effective therapeutics for Alzheimer’s. Personalized, precision medicine approaches represent a potentially effective strategy, and proof-of-concept trials have provided supportive data. Objective: To determine whether a precision medicine approach to Alzheimer’s at the mild cognitive impairment or early dementia stage is effective in a randomized controlled clinical trial. Methods: Seventy-three patients with mild cognitive impairment or early dementia were evaluated for biochemical, microbiological, genetic, epigenetic, and imaging parameters associated with cognitive decline, then assigned randomly to a precision medicine approach or standard of care treatment. Results: Statistically significant effects of the precision medicine approach were observed for overall neurocognitive functioning (d=1.12; 95% CI, 0.56-1.66; p<0.001), memory (d=0.94; 95% CI, 0.40-1.46; p<0.001), executive function (d=0.89; 95% CI, 0.35-1.43; p=0.001), processing speed (d=0.67; 95% CI, 0.14-1.19; p=0.012), self-reported cognitive symptom severity (d=-1.05; 95% CI, -1.60, -0.49, p<0.001), and partner-reported cognitive symptom severity (d=1.26; 95% CI, 0.70-1.81; p<0.001), with MoCA scores showing a trend to improvement (p=0.154). Furthermore, overall health was enhanced, with improvements in blood pressure, body mass index, glycemic index, lipid profiles, and methylation status. Treatment effect size on overall cognitive function exceeded previous trials, being 2-3 times larger than effects of lifestyle interventions and 4-7-times larger than those of anti-amyloid therapies. Conclusion: A personalized, precision medicine approach represents an effective treatment for patients with mild cognitive impairment or early-stage dementia. This treatment improves cognition and overall health rather than simply retarding decline, without significant negative side effects such as brain edema, microhemorrhage, or atrophy.
Background: There is a critical need for effective therapeutics for Alzheimer’s. Personalized, precision medicine approaches represent a potentially effective strategy, and proof-of-concept trials have provided supportive data. Objective: To determine whether a precision medicine approach to Alzheimer’s at the mild cognitive impairment or early dementia stage is effective in a randomized controlled clinical trial. Methods: Seventy-three patients with mild cognitive impairment or early dementia were evaluated for biochemical, microbiological, genetic, epigenetic, and imaging parameters associated with cognitive decline, then assigned randomly to a precision medicine approach or standard of care treatment. Results: Statistically significant effects of the precision medicine approach were observed for overall neurocognitive functioning (d=1.12; 95% CI, 0.56-1.66; p<0.001), memory (d=0.94; 95% CI, 0.40-1.46; p<0.001), executive function (d=0.89; 95% CI, 0.35-1.43; p=0.001), processing speed (d=0.67; 95% CI, 0.14-1.19; p=0.012), self-reported cognitive symptom severity (d=-1.05; 95% CI, -1.60, -0.49, p<0.001), and partner-reported cognitive symptom severity (d=1.26; 95% CI, 0.70-1.81; p<0.001), with MoCA scores showing a trend to improvement (p=0.154). Furthermore, overall health was enhanced, with improvements in blood pressure, body mass index, glycemic index, lipid profiles, and methylation status. Treatment effect size on overall cognitive function exceeded previous trials, being 2-3 times larger than effects of lifestyle interventions and 4-7-times larger than those of anti-amyloid therapies. Conclusion: A personalized, precision medicine approach represents an effective treatment for patients with mild cognitive impairment or early-stage dementia. This treatment improves cognition and overall health rather than simply retarding decline, without significant negative side effects such as brain edema, microhemorrhage, or atrophy.
Posted: 16 April 2026
Fully Analog Spintronic Crossbar Control for Rapid PV Mismatch Management and Maximum-Power Tracking
Pietro Perlo
Posted: 16 April 2026
Enhancing Salt Stress Tolerance in Sorghum bicolor, Sesbania sesban, and Cassia tora Through Arbuscular Mycorrhizal Fungal Symbiosis
Kamal Hassan Suliman
,Khalid M. Al-Rohily
,Gamal Khalid Awadel kraim Mohamed
,Sami Al-Dhumri
,Abdullah Al Mahmud
Posted: 16 April 2026
Adjunctive Vortioxetine in Major Depressive Disorder with Inadequate Response to Antidepressants: A Prospective Real-World Pilot Study from Malaysia
Tharishini Ramachandran
,Ng Chong Guan
,Julian Joon Ip Wong
,Aida Syarinaz Binti Ahmad Adlan
Posted: 16 April 2026
of 5,805